IRIDEX (IRIX) Stock Price
IRIDEX Price
IRIDEX (IRIX) — ISIN US4626841013. The IRIDEX stock price was 1.37 USD in 2026. Revenue was 57.68 M USD. Earnings were -1.23 M USD. P/E ratio was -18.36. IRIDEX operates in the Health sector.
IRIDEX stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of IRIDEX over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how IRIDEX stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing IRIDEX's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | IRIDEX Price |
|---|---|
| 3/17/2026 | 1.37 USD |
| 3/16/2026 | 1.35 USD |
| 3/13/2026 | 1.30 USD |
| 3/12/2026 | 1.34 USD |
| 3/11/2026 | 1.36 USD |
| 3/10/2026 | 1.37 USD |
| 3/9/2026 | 1.32 USD |
| 3/6/2026 | 1.21 USD |
| 3/5/2026 | 1.39 USD |
| 2/26/2026 | 1.48 USD |
| 2/25/2026 | 1.54 USD |
| 2/24/2026 | 1.47 USD |
| 2/23/2026 | 1.44 USD |
| 2/20/2026 | 1.41 USD |
| 2/19/2026 | 1.42 USD |
| 2/18/2026 | 1.41 USD |
IRIDEX Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|
| 53 | 56 | 51 | 48 | 53 | 57 | 61 | 64 |
| 47.22 | 5.66 | -8.93 | -5.88 | 10.42 | 7.55 | 7.02 | 4.92 |
| 41.51 | 44.64 | 41.18 | 39.58 | 35.85 | 33.33 | 31.15 | 29.69 |
| 22 | 25 | 21 | 19 | 19 | 19 | 19 | 19 |
| -5 | -7 | -9 | -8 | -4 | -1 | 0 | 1 |
| -16.67 | 40.00 | 28.57 | -11.11 | -50.00 | -75.00 | – | – |
| 15.42 | 15.94 | 16.13 | 16.44 | 16.44 | 16.44 | 16.44 | 16.44 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales IRIDEX generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IRIDEX retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IRIDEX's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares IRIDEX has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IRIDEX's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
IRIDEX Stock Quarterly Figures
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4e |
|---|---|---|---|---|---|---|---|
| 11 | 12 | 11 | 12 | 11 | 13 | 12 | 14 |
| -8.33 | 9.09 | -8.33 | 9.09 | -8.33 | 18.18 | -7.69 | 16.67 |
| 36.36 | 41.67 | 36.36 | 41.67 | 45.45 | 30.77 | 33.33 | 28.57 |
| 4 | 5 | 4 | 5 | 5 | 4 | 4 | 4 |
| -3 | -2 | -1 | 0 | -1 | 0 | -1 | 0 |
| 50.00 | -33.33 | -50.00 | – | – | – | – | – |
| 16.25 | 16.29 | 16.58 | 16.63 | 16.73 | 16.79 | 17.01 | 17.01 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales IRIDEX generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IRIDEX retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IRIDEX's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares IRIDEX has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IRIDEX's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
IRIDEX stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX business model & stock analysis
IRIDEX SWOT Analysis
Strengths
IRIDEX Corp is a leading global provider of innovative laser-based medical solutions. Their cutting-edge technology and expertise in ophthalmology have positioned them as a trusted brand in the industry.
The company's strong intellectual property portfolio gives them a competitive advantage and protects their innovations from being easily replicated by competitors.
IRIDEX Corp has established a strong distribution network worldwide, enabling them to reach a wide customer base and expand their market presence.
Weaknesses
The company heavily relies on a limited number of key customers for a significant portion of their revenue, making them vulnerable to changes in customer demand and potential loss of key accounts.
IRIDEX Corp faces intense competition from well-established players in the medical device industry. Their ability to differentiate themselves and maintain market share can be challenging.
As a technology-driven company, IRIDEX Corp is exposed to the risk of rapid technological advancements that could render their current products obsolete or less competitive.
Opportunities
The global demand for minimally invasive medical treatments is growing, presenting an opportunity for IRIDEX Corp to expand their market and offer their advanced laser-based solutions to a broader range of medical specialties.
Advancements in healthcare infrastructure and access to medical services in emerging markets provide IRIDEX Corp with an opportunity to tap into new geographical regions and increase their customer base.
The increasing prevalence of ocular diseases, such as glaucoma and diabetic retinopathy, presents a significant market opportunity for IRIDEX Corp to address unmet medical needs and develop targeted treatments.
Threats
IRIDEX Corp operates in a highly regulated industry, subject to rigorous compliance requirements. Any failure to comply with regulations and standards could result in legal and financial consequences.
The ongoing COVID-19 pandemic poses a threat to the company's operations, as it has disrupted global healthcare systems and caused delays in elective surgeries, leading to a potential decrease in demand for their products.
Intense competition and the potential entry of new players in the market pose a threat to IRIDEX Corp's market share and profitability.
IRIDEX Segments
IRIDEX Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
IRIDEX Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
IRIDEX Revenue by Region
3 Years
5 Years
10 Years
Max
Details
IRIDEX Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
IRIDEX historical P/E ratio, EBIT multiple, and P/S ratio
IRIDEX shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX Earnings Estimates
IRIDEX Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 3/26/2026 | -0.02USD | 15.03 MUSD | 2025 Q4 |
| 3/5/2026 | -0.02USD | 0USD | 2025 Q4 |
| 8/12/2025 | -0.09USD | 13.46 MUSD | 2025 Q2 |
| 11/12/2024 | -0.09USD | 12.75 MUSD | 2024 Q3 |
| 5/9/2024 | -0.08USD | 13.46 MUSD | 2024 Q1 |
| 3/7/2024 | -0.09USD | 14.64 MUSD | 2023 Q4 |
| 11/8/2023 | -0.11USD | 15.94 MUSD | 2023 Q3 |
| 8/14/2023 | -0.12USD | 15.12 MUSD | 2023 Q2 |
| 5/10/2023 | -0.12USD | 14.72 MUSD | 2023 Q1 |
| 3/8/2023 | -0.1USD | 15.79 MUSD | 2022 Q4 |
IRIDEX shareholder structure
| % | Name |
|---|---|
9.41316% | |
6.23743% | |
5.81734% | |
3.40787% | |
2.68593% | |
2.20337% | |
1.74520% | |
1.30127% | |
1.07173% | |
1.05642% |
IRIDEX Executives and Management Board
Mr. Patrick Mercer
(53)President, Chief Executive Officer, Chief Operating Officer, Director · since 2018
Mr. William Moore
(76)Independent Director · since 2007
Mr. Bassem Bouhabib
(49)Vice President - International Sales
Mr. Romeo Dizon
(67)Chief Financial Officer · since 2025
Mr. Scott Shuda
(59)Independent Chairman of the Board
IRIDEX Supply Chain
Frequently asked questions about IRIDEX
The business model of IRIDEX Corp focuses on developing, manufacturing, and marketing medical laser systems and delivery devices for the treatment of eye diseases and conditions. With a comprehensive portfolio of products, the company aims to provide innovative solutions to both ophthalmologists and patients. By leveraging its cutting-edge laser technology, IRIDEX Corp aims to improve the standards of care and enhance patient outcomes in the field of ophthalmology.
IRIDEX stock
IRIDEX Peer Group
IRIDEX Ticker
IRIDEX FIGI
All fundamentals and in-depth analysis of IRIDEX
Our stock analysis for IRIDEX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRIDEX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.